YM 543

Drug Profile

YM 543

Alternative Names: YM543

Latest Information Update: 17 Jun 2009

Price : $50

At a glance

  • Originator Kotobuki Seiyaku
  • Developer Astellas Pharma
  • Class Antihyperglycaemics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 29 May 2009 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (PO)
  • 31 Aug 2008 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
  • 13 Feb 2008 Phase-II clinical trials in Type-2 diabetes mellitus in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top